On Tuesday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was -3.26% drop from the session before settling in for the closing price of $82.23. A 52-week range for TARS has been $38.51 – $83.78.
A company in the Healthcare sector has dropped its sales by -66.60% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 52.16%. With a float of $39.10 million, this company’s outstanding shares have now reached $42.45 million.
Tarsus Pharmaceuticals Inc (TARS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tarsus Pharmaceuticals Inc stocks. The insider ownership of Tarsus Pharmaceuticals Inc is 7.88%, while institutional ownership is 104.89%. The most recent insider transaction that took place on Sep 24 ’25, was worth 332,220. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $55.37, taking the stock ownership to the 812,106 shares. Before that another transaction happened on Sep 24 ’25, when Company’s Officer proposed sale 6,000 for $55.37, making the entire transaction worth $332,208.
Tarsus Pharmaceuticals Inc (TARS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.6 earnings per share (EPS) during the time that was better than consensus figure (set at -0.78) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.16% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
You can see what Tarsus Pharmaceuticals Inc (TARS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 1.75 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.41 million. That was inferior than the volume of 0.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 58.13%.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 87.80%, which indicates a significant increase from 49.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.45 in the past 14 days, which was higher than the 2.60 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $72.48, while its 200-day Moving Average is $53.42. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $83.38. Second resistance stands at $87.21. The third major resistance level sits at $89.17. If the price goes on to break the first support level at $77.59, it is likely to go to the next support level at $75.63. The third support level lies at $71.80 if the price breaches the second support level.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are 42,449K outstanding shares of the company, which has a market capitalization of 3.38 billion. As of now, sales total 182,950 K while income totals -115,550 K. Its latest quarter income was 118,700 K while its last quarter net income were -12,590 K.
